Personalized treatments for adult leukemia based on genetic profiles
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies
This study is looking at the unique features of leukemia tumors to create personalized treatment plans that match each patient's specific needs, helping adult leukemia patients get the most effective therapies for their situation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11250349 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular characteristics of individual leukemia tumors to develop personalized treatment plans. By identifying specific genetic and molecular abnormalities in patients, the project aims to match these profiles with targeted therapies that are most likely to be effective. The research involves collaboration among various clinical trial organizations to ensure that patients can access innovative treatments tailored to their unique cancer profiles. The goal is to improve clinical outcomes for adult leukemia patients through a more individualized approach to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with leukemia who have specific genetic or molecular abnormalities.
Not a fit: Patients with leukemia who do not have identifiable genetic or molecular abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for adult leukemia patients.
How similar studies have performed: Other research has shown success in using personalized medicine approaches for cancer treatment, indicating a promising avenue for this type of investigation.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Byrd, John C. — University of Cincinnati
- Study coordinator: Byrd, John C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.